Myocardial T1 mapping: Hope or hype?

Circulation Journal

Volumn 79, Issue 3, 2015, Pages 487-494

  Bulluck, Heerajnarain ^a,b   Maestrini, Viviana ^a,d   Rosmini, Stefania ^a   Abdel Gadir, Amna ^a,b   Treibel, Thomas A ^a,b   Castelletti, Silvia ^a   Bucciarelli Ducci, Chiara ^c   Manisty, Charlotte ^a,b   Moon, James C ^a,b  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Biomarkers; Cardiovascular MRI; Diffuse fibrosis; Imaging; T1 mapping

Indexed keywords

GADOLINIUM;

ACUTE HEART INFARCTION; AORTA STENOSIS; BLEEDING; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL TRIAL (TOPIC); CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DRUG DESIGN; EXTRACELLULAR SPACE; FABRY DISEASE; FIBROSING ALVEOLITIS; HEART AMYLOIDOSIS; HEART ATRIUM FIBRILLATION; HEART EDEMA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IRON OVERLOAD; METAPLASIA; MYOCARDIAL DISEASE; MYOCARDITIS; REVIEW; SIDEROSIS; STANDARDIZATION; TREATMENT RESPONSE; FIBROSIS; HEART; HEART DISEASES; HEART MUSCLE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHYSIOLOGIC MONITORING; PROCEDURES; RADIOGRAPHY;

FIBROSIS; HEART; HEART DISEASES; HUMANS; MAGNETIC RESONANCE IMAGING; MONITORING, PHYSIOLOGIC; MYOCARDIUM;

EID: 84923521897     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-15-0054     Document Type: Review

References (82)

1. Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006; 48: 1977–1985.
2. Jiji RS, Kramer CM. Cardiovascular magnetic resonance: Applications in daily practice. Cardiol Rev 2011; 19: 246–254.
3. Karamitsos TD, Neubauer S. The prognostic value of late gadolinium enhancement CMR in nonischemic cardiomyopathies. Curr Cardiol Rep 2013; 15: 326.
4. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E, Society for Cardiovascular Magnetic Resonance Board of Trustees Task Force on Standardized Protocols. Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: Board of trustees task force on standardized protocols. J Cardiovasc Magn Reson 2008; 10: 35.
5. Schalla S, Bekkers SC, Dennert R, van Suylen RJ, Waltenberger J, Leiner T, et al. Replacement and reactive myocardial fibrosis in idiopathic dilated cardiomyopathy: Comparison of magnetic resonance imaging with right ventricular biopsy. Eur J Heart Fail 2010; 12: 227–231.
6. Mewton N, Liu CY, Croisille P, Bluemke D, Lima JA. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol 2011; 57: 891–903.
7. Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, et al. Myocardial T1 mapping and extracellular volume quantification: A Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson 2013; 15: 92.
8. Piechnik SK, Ferreira VM, Lewandowski AJ, Ntusi NA, Banerjee R, Holloway C, et al. Normal variation of magnetic resonance T1 relaxation times in the human population at 1.5 T using ShMOLLI. J Cardiovasc Magn Reson 2013; 15: 13.
9. Coelho-Filho OR, Shah RV, Mitchell R, Neilan TG, Moreno H Jr, Simonson B, et al. Quantification of cardiomyocyte hypertrophy by cardiac magnetic resonance: Implications for early cardiac remodeling. Circulation 2013; 128: 1225–1233.
10. Bull S, White SK, Piechnik SK, Flett AS, Ferreira VM, Loudon M, et al. Human non-contrast T1 values and correlation with histology in diffuse fibrosis. Heart 2013; 99: 932–937.
11. Ferreira VM, Piechnik SK, Dall’Armellina E, Karamitsos TD, Francis JM, Choudhury RP, et al. Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: A comparison to T2-weighted cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012; 14: 42.
12. Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 2013; 6: 488–497.
13. Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 2013; 6: 392–398.
14. Sado DM, Maestrini V, Piechnik SK, Banypersad SM, White SK, Flett AS, et al. Noncontrast myocardial T1 mapping using cardiovascular magnetic resonance for iron overload. J Magn Reson Imaging 2014 August 8, doi:10.1002/jmri.24727.
15. Pedersen SF, Thrysoe SA, Robich MP, Paaske WP, Ringgaard S, Botker HE, et al. Assessment of intramyocardial hemorrhage by T1-weighted cardiovascular magnetic resonance in reperfused acute myocardial infarction. J Cardiovasc Magn Reson 2012; 14: 59.
16. Jellis CL, Kwon DH. Myocardial T1 mapping: Modalities and clinical applications. Cardiovasc Diagn Ther 2014; 4: 126–137.
17. Rienks M, Papageorgiou AP, Frangogiannis NG, Heymans S. Myocardial extracellular matrix: An ever-changing and diverse entity. Circ Res 2014; 114: 872–888.
18. Messroghli DR, Greiser A, Frohlich M, Dietz R, Schulz-Menger J. Optimization and validation of a fully-integrated pulse sequence for modified Look-Locker inversion-recovery (MOLLI) T1 mapping of the heart. J Magn Reson Imaging 2007; 26: 1081–1086.
19. Chin CW, Semple S, Malley T, White AC, Mirsadraee S, Weale PJ, et al. Optimization and comparison of myocardial T1 techniques at 3T in patients with aortic stenosis. Eur Heart J Cardiovasc Imaging 2014; 15: 556–565.
20. Flett AS, Sado DM, Quarta G, Mirabel M, Pellerin D, Herrey AS, et al. Diffuse myocardial fibrosis in severe aortic stenosis: An equilibrium contrast cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging 2012; 13: 819–826.
21. White SK, Sado DM, Fontana M, Banypersad SM, Maestrini V, Flett AS, et al. T1 mapping for myocardial extracellular volumewith measurement by CMR: Bolus only versus primed infusion technique. JACC Cardiovasc Imaging 2013; 6: 955–962.
22. Jerosch-Herold M, Sheridan DC, Kushner JD, Nauman D, Burgess D, Dutton D, et al. Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2008; 295: H1234–H1242.
23. Kellman P, Wilson JR, Xue H, Ugander M, Arai AE. Extracellular volume fraction mapping in the myocardium. Part 1: Evaluation of an automated method. J Cardiovasc Magn Reson 2012; 14: 63.
24. Look DC, Locker DR. Time saving in measurement of NMR and EPR relaxation times. Rev Sci Instrum 1970; 41: 250–251.
25. Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU, Ridgway JP. Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn Reson Med 2004; 52: 141–146.
26. Piechnik SK, Ferreira VM, Dall’Armellina E, Cochlin LE, Greiser A, Neubauer S, et al. Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. J Cardiovasc Magn Reson 2010; 12: 69.
27. Chow K, Flewitt JA, Green JD, Pagano JJ, Friedrich MG, Thompson RB. Saturation recovery single-shot acquisition (SASHA) for myocardial T(1) mapping. Magn Reson Med 2014; 71: 2082–2095.
28. Weingartner S, Akcakaya M, Basha T, Kissinger KV, Goddu B, Berg S, et al. Combined saturation/inversion recovery sequences for improved evaluation of scar and diffuse fibrosis in patients with arrhythmia or heart rate variability. Magn Reson Med 2014; 71: 1024–1034.
29. Higgins DM, Moon JC. Review of T1 mapping methods: Comparative effectiveness including reproducibility issues. Curr Cardiovasc Imaging Rep 2014; 7: 9252.
30. Roujol S, Weingartner S, Foppa M, Chow K, Kawaji K, Ngo LH, et al. Accuracy, precision, and reproducibility of four T1 mapping sequences: A head-to-head comparison of MOLLI, ShMOLLI, SASHA, and SAPPHIRE. Radiology 2014; 272: 683–689.
31. Kellman P, Hansen MS. T1-mapping in the heart: Accuracy and precision. J Cardiovasc Magn Reson 2014; 16: 2.
32. Fontana M, White SK, Banypersad SM, Sado DM, Maestrini V, Flett AS, et al. Comparison of T1 mapping techniques for ECV quantification: Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR. J Cardiovasc Magn Reson 2012; 14: 88.
33. Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007; 50: 2101–2110.
34. Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK, et al. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging 2014; 7: 157–165.
35. Banypersad SM, Sado DM, Flett AS, Gibbs SD, Pinney JH, Maestrini V, et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: An equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging 2013; 6: 34–39.
36. Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J 2015; 36: 244–251.
37. Banypersad SM, Fontana M, Maestrini V, Sado D, White SK, Treibel TA, et al. Cardiac amyloid burden assessment by T1 mapping predicts survival in patients with systemic AL amyloidosis: A 2 year follow-up study. J Cardiovasc Magn Reson 2014; 16: O5.
38. O’Mahony C, Elliott P. Anderson-Fabry disease and the heart. Prog Cardiovasc Dis 2010; 52: 326–335.
39. Thompson RB, Chow K, Khan A, Chan A, Shanks M, Paterson I, et al. T(1) mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex. Circ Cardiovasc Imaging 2013; 6: 637–645.
40. Pica S, Sado DM, Maestrini V, Fontana M, White SK, Treibel T, et al. Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2014; 16: 99.
41. Poggiali E, Cassinerio E, Zanaboni L, Cappellini MD. An update on iron chelation therapy. Blood Transfus 2012; 10: 411–422.
42. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2008; 10: 42.
43. Dall’Armellina E, Karia N, Lindsay AC, Karamitsos TD, Ferreira V, Robson MD, et al. Dynamic changes of edema and late gadoliniumenhancement after acute myocardial infarction and their relationship to functional recovery and salvage index. Circ Cardiovasc Imaging 2011; 4: 228–236.
44. Chan W, Duffy SJ, White DA, Gao XM, Du XJ, Ellims AH, et al. Acute left ventricular remodeling following myocardial infarction: Coupling of regional healing with remote extracellular matrix expansion. JACC Cardiovasc Imaging 2012; 5: 884–893.
45. Ugander M, Oki AJ, Hsu LY, Kellman P, Greiser A, Aletras AH, et al. Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Eur Heart J 2012; 33: 1268–1278.
46. Messroghli DR, Walters K, Plein S, Sparrow P, Friedrich MG, Ridgway JP, et al. Myocardial T1 mapping: Application to patients with acute and chronic myocardial infarction. Magn Reson Med 2007; 58: 34–40.
47. Langhans B, Nadjiri J, Jahnichen C, Kastrati A, Martinoff S, Hadamitzky M. Reproducibility of area at risk assessment in acute myocardial infarction by T1- and T2-mapping sequences in cardiac magnetic resonance imaging in comparison to Tc99 m-sestamibi SPECT. Int J Cardiovasc Imaging 2014; 30: 1357–1363.
48. Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol 2008; 52: 1574–1580.
49. Iles LM, Ellims AH, Llewellyn H, Hare JL, Kaye DM, McLean CA, et al. Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. Eur Heart J Cardiovasc Imaging 2015; 16: 14–22.
50. Su MY, Lin LY, Tseng YH, Chang CC, Wu CK, Lin JL, et al. CMRverified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF. JACC Cardiovasc Imaging 2014; 7: 991–997.
51. Mascherbauer J, Marzluf BA, Tufaro C, Pfaffenberger S, Graf A, Wexberg P, et al. Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction. Circ Cardiovasc Imaging 2013; 6: 1056–1065.
52. Wong TC, Piehler KM, Kang IA, Kadakkal A, Kellman P, Schwartzman DS, et al. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J 2014; 35: 657–664.
53. Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28: 230–268.
54. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, et al. 2008 Focused update incorporated into the ACC/ AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2008; 52: e1–e142, doi:10.1016/j.jacc.2008.05.007.
55. Taylor J. ESC/EACTS guidelines on the management of valvular heart disease. Eur Heart J 2012; 33: 2371–2372.
56. Milano AD, Faggian G, Dodonov M, Golia G, Tomezzoli A, Bortolotti U, et al. Prognostic value of myocardial fibrosis in patients with severe aortic valve stenosis. J Thorac Cardiovasc Surg 2012; 144: 830–837.
57. Shin S, Park PW, Han WS, Sung KI, Kim WS, Lee YT. Mass reduction and functional improvement of the left ventricle after aortic valve replacement for degenerative aortic stenosis. The Korean J Thorac Cardiovasc Surg 2011; 44: 399–405.
58. Weidemann F, Herrmann S, Stork S, Niemann M, Frantz S, Lange V, et al. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation 2009; 120: 577–584.
59. Lee SP, Lee W, Lee JM, Park EA, Kim HK, Kim YJ, et al. Assessment of diffuse myocardial fibrosis by using MR imaging in asymptomatic patients with aortic stenosis. Radiology 2015; 274: 359–369.
60. Singh A, Ford I, Greenwood JP, Khan JN, Uddin A, Berry C, et al. Rationale and design of the PRognostic Importance of MIcrovascular Dysfunction in asymptomatic patients with Aortic Stenosis (PRIMID-AS): A multicentre observational study with blinded investigations. BMJ Open 2013; 3: e004348, doi:10.1136/bmjopen-2013-004348.
61. Sibley CT, Noureldin RA, Gai N, Nacif MS, Liu S, Turkbey EB, et al. T1 Mapping in cardiomyopathy at cardiac MR: Comparison withendomyocardial biopsy. Radiology 2012; 265: 724–732.
62. Dass S, Suttie JJ, Piechnik SK, Ferreira VM, Holloway CJ, Banerjee R, et al. Myocardial tissue characterization using magnetic resonance noncontrast T1 mapping in hypertrophic and dilated cardiomyopathy. Circ Cardiovasc Imaging 2012; 5: 726–733.
63. Sado DM, Flett AS, Banypersad SM, White SK, Maestrini V, Quarta G, et al. Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart 2012; 98: 1436–1441.
64. Puntmann VO, Voigt T, Chen Z, Mayr M, Karim R, Rhode K, et al. Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging 2013; 6: 475–484.
65. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: Preliminary validation in humans. Circulation 2010; 122: 138–144.
66. Florian A, Ludwig A, Rosch S, Yildiz H, Sechtem U, Yilmaz A. Myocardial fibrosis imaging based on T1-mapping and extracellular volume fraction (ECV) measurement in muscular dystrophy patients: Diagnostic value compared with conventional late gadolinium enhancement (LGE) imaging. Eur Heart J Cardiovasc Imaging 2014; 15: 1004–1012.
67. Vermes E, Pucheux J, Delhommais A, Alison D, Brunereau L. Cardiac magnetic resonance T1 mapping pre and post contrast in heart transplant patients with clinical antibody-mediated rejection: A preliminary experience. Journal of Cardiovascular Magnetic Resonance 2014; 16: P100.
68. Edwards NC, Moody WE, Chue CD, Ferro CJ, Townend JN, Steeds RP. Defining the natural history of uremic cardiomyopathy in chronic kidney disease: The role of cardiovascular magnetic resonance. JACC Cardiovasc Imaging 2014; 7: 703–714.
69. Thuny F, Lovric D, Schnell F, Bergerot C, Ernande L, Cottin V, et al. Quantification of myocardial extracellular volume fraction with cardiac MR imaging for early detection of left ventricle involvement in systemic sclerosis. Radiology 2014; 271: 373–380.
70. Ntusi NA, Piechnik SK, Francis JM, Ferreira VM, Rai AB, Matthews PM, et al. Subclinical myocardial inflammation and diffuse fibrosis are common in systemic sclerosis: A clinical study using myocardial T1-mapping and extracellular volume quantification. J cardiovasc Magn Reson 2014; 16: 21.
71. Puntmann VO, D’Cruz D, Smith Z, Pastor A, Choong P, Voigt T, et al. Native myocardial T1 mapping by cardiovascular magnetic resonance imaging in subclinical cardiomyopathy in patients with systemic lupus erythematosus. Circ Cardiovasc Imaging 2013; 6: 295–301.
72. Friedrich MG, Marcotte F. Cardiac magnetic resonance assessment of myocarditis. Circ Cardiovasc Imaging 2013; 6: 833–839.
73. Park CH, Choi EY, Greiser A, Paek MY, Hwang SH, Kim TH. Diagnosis of acute global myocarditis using cardiac MRI with quantitative T1 and T2 mapping: Case report and literature review. Korean J Radiol 2013; 14: 727–732.
74. Verhaert D, Thavendiranathan P, Giri S, Mihai G, Rajagopalan S, Simonetti OP, et al. Direct T2 quantification of myocardial edema in acute ischemic injury. JACC Cardiovasc Imaging 2011; 4: 269–278.
75. Ferreira VM, Piechnik SK, Dall’Armellina E, Karamitsos TD, Francis JM, Ntusi N, et al. T(1) mapping for the diagnosis of acute myocarditis using CMR: Comparison to T2-weighted and late gadolinium enhanced imaging. JACC Cardiovasc Imaging 2013; 6: 1048–1058.
76. Luetkens JA, Doerner J, Thomas DK, Dabir D, Gieseke J, Sprinkart AM, et al. Acute myocarditis: Multiparametric cardiac MR imaging. Radiology 2014; 273: 383–392.
77. Ferreira VM, Piechnik SK, Dall’Armellina E, Karamitsos TD, Francis JM, Ntusi N, et al. Native T1-mapping detects the location, extent and patterns of acute myocarditis without the need for gadolinium contrast agents. J Cardiovasc Magn Reson 2014; 16: 36.
78. Burstein B, Nattel S. Atrial fibrosis: Mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008; 51: 802–809.
79. Beinart R, Khurram IM, Liu S, Yarmohammadi H, Halperin HR, Bluemke DA, et al. Cardiac magnetic resonance T1 mapping of left atrial myocardium. Heart Rhythm 2013; 10: 1325–1331.
80. Ling LH, McLellan AJ, Taylor AJ, Iles LM, Ellims AH, Kumar S, et al. Magnetic resonance post-contrast T1 mapping in the human atrium: Validation and impact on clinical outcome following catheter ablation for atrial fibrillation. Heart Rhythm 2014; 11: 1551–1559.
81. Ling LH, Kistler PM, Ellims AH, Iles LM, Lee G, Hughes GL, et al. Diffuse ventricular fibrosis in atrial fibrillation: Noninvasive evaluation and relationships with aging and systolic dysfunction. J Am Coll Cardiol 2012; 60: 2402–2408.
82. Ling LH, Kalman JM, Ellims AH, Iles LM, Medi C, Sherratt C, et al. Diffuse ventricular fibrosis is a late outcome of tachycardiamediated cardiomyopathy after successful ablation. Circ Arrhythm Electrophysiol 2013; 6: 697–704.